- STAT+: Pharmalittle: We’re reading about a Biogen Alzheimer’s drug, skyrocketing 340B drug sales, and moreAn Alzheimer’s drug from Biogen slowed cognitive decline in a mid-stage trial at roughly comparable rates as approved medicinesSTAT · 12d ago↗ source
- Nava Therapeutics emerges with $89M for lipid nanoparticlesNava Therapeutics, a secretive startup that’s been working on a new generation of lipid nanoparticles that target the bone marrow, immune cells and the kidney, has raised $89 million, the company t…Endpoints · 12d ago↗ source
- Braveheart files for IPO to fund Phase 3 of Hengrui's Cytokinetics rivalBiotechs are sprinting to the IPO queue. In the industry's fourth IPO filing in two weeks, Braveheart Bio is seeking a Nasdaq listing to fuel Phase 3 testing of a cardio drug that could potential…